再生(生物学)
2型糖尿病
糖尿病
1型糖尿病
电流(流体)
医学
重症监护医学
生物
内分泌学
细胞生物学
工程类
电气工程
作者
Arthur Rech Tondin,Giacomo Lanzoni
出处
期刊:BioDrugs
[Adis, Springer Healthcare]
日期:2025-02-07
卷期号:39 (2): 261-280
被引量:35
标识
DOI:10.1007/s40259-025-00703-7
摘要
Type 1 diabetes (T1D) is a chronic autoimmune disorder characterized by the destruction of insulin-producing beta cells in the pancreas, leading to insulin deficiency and chronic hyperglycemia. The main current therapeutic strategies for clinically overt T1D - primarily exogenous insulin administration combined with blood glucose monitoring - fail to fully mimic physiological insulin regulation, often resulting in suboptimal or insufficient glycemic control. Islet cell transplantation has emerged as a promising avenue for functionally replacing endogenous insulin production and achieving long-term glycemic stability. Here, we provide an overview of current islet replacement strategies, ranging from islet transplantation to stem cell-derived islet cell transplantation, and highlight emerging approaches such as immunoengineering. We examine the advancements in immunosuppressive protocols to enhance graft survival, innovative encapsulation, and immunomodulation techniques to protect transplanted islets, and the ongoing challenges in achieving durable and functional islet integration. Additionally, we discuss the latest clinical outcomes, the potential of gene editing technologies, and the emerging strategies for islet cell regeneration. This review aims to highlight the potential of these approaches to transform the management of T1D and improve the quality of life of individuals affected by this condition.
科研通智能强力驱动
Strongly Powered by AbleSci AI